The striking success of ticagrelor in PLATO when compared with recent important but far less impressive antiplatelet trials suggests the fundamental difference of ticagrelor from thienopyridines, such as ticlopidone, clopidogrel, and prasugrel. In fact, being a P2Y12 platelet receptor inhibitor, ticagrelor does not belong to the thienopyridines. The agent is a carbocyclic nucleoside, representing a ‘first-in-class’ cyclopentyl-triazolo-pyrimidine. The chemical structure of ticagrelor indicates that its primary mechanism of action may be via up-regulating plasma and intracellular adenosine content, especially considering the obvious similarity of their molecules. Since ticagrelor does not require hepatic metabolization, an adenosine-promoting mechanism of action is the most likely responsible pathway. Some of the delayed and growing mortality advantage of ticagrelor over clopidogrel cannot be explained by pure antiplatelet properties of the drug, but may be attributed to the off-target pleiothropic effects of the novel agent. An adenosine-mediated mechanism is most likely responsible for the fundamental difference of ticagrelor from established antiplatelet agents, and resulted in less heart failure deaths, and reduction of fatal arrhythmias. However, massive prevention of vascular death mismatched with conventional myocardial infarction rates, and reduction of sepsis-related mortality still lacks reasonable explanation, being under the scope of the regulatory agencies around the world. Future randomized trials of ticagrelor in acute heart failure, sudden death prevention, and treatment of atrial fibrillation are warranted, and may expand our understanding of the mechanism of action of pyrimidines in general, and ticagrelor in particular.

Keywords:
Adenosine, Arrhythmia, Heart failure, Mortality, Ticagrelor
1.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; the PLATO Investigators: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.
3.
Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G: Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation 1990;82:17–26.
4.
Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S; CURRENT-OASIS 7 Investigators: Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930–942.
5.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; the TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.
6.
VAN Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ: Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009;7:1556–1565.
7.
Serebruany VL: Adenosine release: a potential explanation for the benefits of ticagrelor in PLATO? Am Heart J 2010, in press.
8.
Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038–1047.
9.
Linden J: Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Ann Rev Pharmacol Toxicol 2001;41:775–787.
10.
ISIS-2 Trial Investigators: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349–360.
11.
COMMIT Collaborative Group: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607–1621.
12.
Malkin CJ, Channer KS: Life-saving or life-prolonging? Interpreting trial data and survival curves for patients with congestive heart failure. Eur J Heart Fail 2005;7:143–148.
13.
Cohen MV, Downey JM: Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 2008;103:203–215.
14.
Headrick JP, Lasley RD: Adenosine receptors and reperfusion injury of the heart. Handb Exp Pharmacol 2009;193:189–214.
15.
Yildiz G, Demiryürek AT, Gümüşel B, Lippton H: Ischemic preconditioning modulates ischemia-reperfusion injury in the rat lung: role of adenosine receptors. Eur J Pharmacol 2007;556:144–150.
16.
Germack R, Dickenson JM: Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 2005;39:429–442.
17.
Narayan P, Mentzer RM Jr, Lasley RD: Adenosine A1 receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes. J Mol Cell Cardiol 2001;33:121–129.
18.
Sadigh B, Shahgaldi K, Sylvén C, Quintana M, Winter R: Preconditioning effects of adenosine in patients with severe coronary artery disease but preserved coronary flow reserve. Cor Artery Dis 2009;20:354–359.
19.
Canyon SJ, Dobson GP: Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat. Am J Physiol Heart Circ Physiol 2004;287:H1286–H1295.
20.
Riccardi A, Arboscello E, Ghinatti M, Minuto P, Lerza R: Adenosine in the treatment of supraventricular tachycardia: 5 years of experience (2002–2006). Am J Emerg Med 2008;26:879–882.
21.
Fredholm BB: Adenosine receptors as drug targets. Exp Cell Res 2010;316:1284–1288.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.